1. Home
  2. ANGH vs CTXR Comparison

ANGH vs CTXR Comparison

Compare ANGH & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anghami Inc.

ANGH

Anghami Inc.

HOLD

Current Price

$4.15

Market Cap

22.1M

ML Signal

HOLD

Logo Citius Pharmaceuticals Inc.

CTXR

Citius Pharmaceuticals Inc.

HOLD

Current Price

$0.85

Market Cap

19.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANGH
CTXR
Founded
2012
2007
Country
United Arab Emirates
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.1M
19.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ANGH
CTXR
Price
$4.15
$0.85
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$6.00
AVG Volume (30 Days)
2.2M
1.4M
Earning Date
04-30-2026
02-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$96,736,848.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$147.57
P/E Ratio
N/A
N/A
Revenue Growth
85.06
N/A
52 Week Low
$2.25
$0.63
52 Week High
$8.40
$4.51

Technical Indicators

Market Signals
Indicator
ANGH
CTXR
Relative Strength Index (RSI) 79.17 38.71
Support Level $2.30 $0.76
Resistance Level $2.71 $1.18
Average True Range (ATR) 0.30 0.11
MACD 0.16 -0.02
Stochastic Oscillator 98.97 38.90

Price Performance

Historical Comparison
ANGH
CTXR

About ANGH Anghami Inc.

Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with a catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner Music. It generates the majority of its revenue from subscriptions.

About CTXR Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.

Share on Social Networks: